ANNX Annexon, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1528115 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY3.9%
TTM EPS YoY28.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-130.8%
ROA-83.0%
ROIC (approx.)-293.6%
Asset turnover—
Leverage & solvency
Liabilities / assets43.0%
Debt / equity0.35x
Current ratio5.79x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.95x
Accruals ratio-4.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $184.70M | $119.45M |
| SG&A expense | $31.71M | $34.62M |
| Operating income | -$216.41M | -$154.07M |
| Pretax income | -$206.69M | -$138.20M |
| Income tax | $0 | $0 |
| Net income | -$206.69M | -$138.20M |
| EBITDA | -$214.24M | -$151.92M |
| EPS (basic) | -1.34 | -1.01 |
| EPS (diluted) | -1.34 | -1.01 |
| Dividends declared per share | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 155.11M | 137.40M |
| Balance sheet | ||
| Cash & equivalents | $162.05M | $50.53M |
| Short-term investments | $76.29M | $262.52M |
| Current assets | $242.19M | $316.46M |
| PP&E, net | $10.62M | $12.64M |
| Total assets | $277.57M | $350.07M |
| Current liabilities | $42.63M | $30.51M |
| Long-term debt | $0 | — |
| Total debt | $0 | — |
| Total liabilities | $65.92M | $56.97M |
| Shareholders' equity | $211.65M | $293.11M |
| Net debt | -$162.05M | — |
| Shares outstanding | 149.36M | 109.38M |
| Cash flow statement | ||
| Operating cash flow | -$186.36M | -$118.01M |
| Capital expenditure | $137,000 | $15,000 |
| Free cash flow | -$186.49M | -$118.02M |
| Investing cash flow | $190.05M | -$218.80M |
| Financing cash flow | $108.86M | $161.21M |
| Depreciation & amortization | $2.17M | $2.15M |
| Stock-based compensation | $16.42M | $19.43M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.